Skip to main content

Market Overview

Sigma-Aldrich Announces Exclusive Distribution Agreement with IROA Technologies, LLC

Share:

Provides Researchers with Global Access to IROA Technologies' Mass Spectrometry Metabolite Library of Standards

ST. LOUIS, Sept. 17, 2015 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology Company, announced today it has signed an exclusive global distribution agreement with IROA Technologies, LLC to distribute IROA's Mass Spectrometry Metabolite Library of Standards™ (MSMLS). The agreement partners IROA's MSMLS product portfolio and software with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.

MSMLS is a collection of high-quality small molecules that span a broad range of primary metabolism. These are high purity (>95%) compounds supplied in an economical, ready-to-use format. The library of standards is most commonly used to provide retention times and spectra for key metabolic compounds, help optimize mass spectrometry analytical protocols and qualify and quantify mass spectrometry sensitivity and limit of detection.

Under the agreement, Sigma-Aldrich has worldwide rights to sell IROA Technologies' Mass Spectrometry Metabolite Library of Standards. Sigma-Aldrich will employ its sales, marketing and eCommerce expertise and leverage the strength of its relationships with the scientific community to present and distribute MSMLS and the corresponding software, MSMLSDiscovery™.

"Our partnership with IROA, an award-winning innovative leader in the field of metabolomics, reflects Sigma-Aldrich's commitment to meet customer needs by supplying the most cutting-edge and efficient technologies and our mission to enable science to improve the quality of life," said Josef Zihlmann, Vice President of Product Management and R&D.

To learn more about Sigma-Aldrich's distribution of the Mass Spectrometry Metabolite Library of Standards, visit www.sigma-aldrich.com/msmls.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "is expected" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that this or any other product offering will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding this product offering could be affected by, among other things, the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes 250,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has approximately 9,700 employees worldwide and had sales of $2.79 billion in 2014.

For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co., LLC registered in the US and other countries. MSMLS and MSMLSDiscovery are trademarks of IROA Technologies, LLC.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sigma-aldrich-announces-exclusive-distribution-agreement-with-iroa-technologies-llc-300144544.html

SOURCE Sigma-Aldrich

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com